Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

被引：2696

作者：

Vetizou, Marie ^{[1
,2
,3
]}

Pitt, Jonathan M. ^{[1
,2
,3
]}

Daillere, Romain ^{[1
,2
,3
]}

Lepage, Patricia ^{[4
]}

Waldschmitt, Nadine ^{[5
]}

Flament, Caroline ^{[1
,2
,6
]}

Rusakiewicz, Sylvie ^{[1
,2
,6
]}

Routy, Bertrand ^{[1
,2
,3
,6
]}

Roberti, Maria P. ^{[1
,2
,6
]}

Duong, Connie P. M. ^{[1
,2
,6
]}

Poirier-Colame, Vichnou ^{[1
,2
,6
]}

Roux, Antoine ^{[1
,2
,7
]}

Becharef, Sonia ^{[1
,2
,6
]}

Formenti, Silvia ^{[8
]}

Golden, Encouse ^{[8
]}

Cording, Sascha ^{[9
]}

Eberl, Gerard ^{[9
]}

Schlitzer, Andreas ^{[10
]}

Ginhoux, Florent ^{[10
]}

Mani, Sridhar ^{[11
,12
]}

Yamazaki, Takahiro ^{[1
,2
]}

Jacquelot, Nicolas ^{[1
,2
,3
]}

Enot, David P. ^{[1
,13
]}

Berard, Marion ^{[14
]}

Nigou, Jerome ^{[15
,16
]}

Opolon, Paule ^{[1
]}

Eggermont, Alexander ^{[1
,2
,17
]}

Woerther, Paul-Louis ^{[18
]}

Chachaty, Elisabeth ^{[18
]}

Chaput, Nathalie ^{[1
,19
]}

Robert, Caroline ^{[1
,20
]}

Mateus, Christina ^{[1
]}

Kroemer, Guido ^{[13
,21
,22
,23
]}

Raoult, Didier ^{[24
]}

Boneca, Ivo Gomperts ^{[25
,26
]}

Carbonnel, Franck ^{[27
]}

Chamaillard, Mathias

Zitvogel, Laurence ^{[1
,2
,3
,6
]}

机构：

[1] Inst Cancerol Gustave Roussy Canc Campus GRCC, 114 Rue Edouard, F-94805 Villejuif, France

[2] GRCC, INSERM, U1015, Villejuif, France

[3] Univ Paris Sud, Univ Paris 11, Le Kremlin Bicetre, France

[4] INRA, Micalis UMR1319, F-78360 Jouy En Josas, France

[5] Univ Lille, Ctr Hosp Reg Univ Lille, Inst Pasteur Lille,CNRS,INSERM, U1019,UMR 8204,Ctr Infect Immunite Lille CIIL, F-59000 Lille, France

[6] Ctr Clin Invest Biotherapies Canc 1428, Villejuif, France

[7] Univ Paris 05, Sorbonne Paris Cite, Paris, France

[8] NYU, Dept Radiat Oncol, New York, NY USA

[9] Inst Pasteur, Microenvironm & Immun Unit, Paris, France

[10] Agcy Sci Technol & Res, A STAR, Singapore Immunol Network SIgN, Singapore, Singapore

[11] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA

[12] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA

[13] GRCC, Metab Platform, Villejuif, France

[14] Inst Pasteur, Animalerie Cent, Paris, France

[15] Inst Pharmacol & Biol Struct IPBS, CNRS, Toulouse, France

[16] Univ Paul Sabatier, Univ Toulouse, IPBS, F-31077 Toulouse, France

[17] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France

[18] GRCC, Serv Microbiol, Villejuif, France

[19] GRCC, CNRS, INSERM, US 23,Lab Immunomonitoring Oncol,UMS 3655, Villejuif, France

[20] GRCC, INSERM, U981, Villejuif, France

[21] INSERM, U848, Villejuif, France

[22] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, INSERM, U1138, Paris, France

[23] Assistance Publ Hop Paris, Hop Europeen Georges Pom, Pole Biol, Paris, France

[24] Aix Marseille Univ, Univ Mediterranee, Fac Med, Unite Rickettsies, Marseille, France

[25] Inst Pasteur, Unit Biol & Genet Bacterial Cell Wall, Paris, France

[26] INSERM, Equipe Avenir, Paris, France

[27] Assistance Publ Hop Paris, Hop Bicetre, Dept Gastroenterol, Paris, France

来源：

SCIENCE | 2015年 / 350卷 / 6264期

基金：

欧洲研究理事会;

关键词：

T-CELLS; ANTIBODY; MOLECULE; CANCER; INNATE; MODEL;

D O I：

10.1126/science.aad1329

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, Tcell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.

引用

页码：1079 / +

页数：7

共 50 条

[1] CTLA-4 blockade and the renaissance of cancer immunotherapy
Mocellin, Simone
Nitti, Donato
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2013, 1836 (02): : 187 - 196
[2] A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du
Fei Tang
Mingyue Liu
Juanjuan Su
Yan Zhang
Wei Wu
Martin Devenport
Christopher A Lazarski
Peng Zhang
Xu Wang
Peiying Ye
Changyu Wang
Eugene Hwang
Tinghui Zhu
Ting Xu
Pan Zheng
Yang Liu
Cell Research, 2018, 28 : 416 - 432
[3] A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, Xuexiang
Tang, Fei
Liu, Mingyue
Su, Juanjuan
Zhang, Yan
Wu, Wei
Devenport, Martin
Lazarski, Christopher A.
Zhang, Peng
Wang, Xu
Ye, Peiying
Wang, Changyu
Hwang, Eugene
Zhu, Tinghui
Xu, Ting
Zheng, Pan
Liu, Yang
CELL RESEARCH, 2018, 28 (04) : 416 - 432
[4] Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Miles C. Andrews
Connie P. M. Duong
Vancheswaran Gopalakrishnan
Valerio Iebba
Wei-Shen Chen
Lisa Derosa
Md Abdul Wadud Khan
Alexandria P. Cogdill
Michael G. White
Matthew C. Wong
Gladys Ferrere
Aurélie Fluckiger
Maria P. Roberti
Paule Opolon
Maryam Tidjani Alou
Satoru Yonekura
Whijae Roh
Christine N. Spencer
Irina Fernandez Curbelo
Luis Vence
Alexandre Reuben
Sarah Johnson
Reetakshi Arora
Golnaz Morad
Matthew Lastrapes
Erez N. Baruch
Latasha Little
Curtis Gumbs
Zachary A. Cooper
Peter A. Prieto
Khalida Wani
Alexander J. Lazar
Michael T. Tetzlaff
Courtney W. Hudgens
Margaret K. Callahan
Matthew Adamow
Michael A. Postow
Charlotte E. Ariyan
Pierre-Olivier Gaudreau
Luigi Nezi
Didier Raoult
Catalin Mihalcioiu
Arielle Elkrief
Rossanna C. Pezo
Lauren E. Haydu
Julie M. Simon
Hussein A. Tawbi
Jennifer McQuade
Patrick Hwu
Wen-Jen Hwu
Nature Medicine, 2021, 27 : 1432 - 1441
[5] Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Andrews, Miles C.
Duong, Connie P. M.
Gopalakrishnan, Vancheswaran
Iebba, Valerio
Chen, Wei-Shen
Derosa, Lisa
Khan, Md Abdul Wadud
Cogdill, Alexandria P.
White, Michael G.
Wong, Matthew C.
Ferrere, Gladys
Fluckiger, Aurelie
Roberti, Maria P.
Opolon, Paule
Alou, Maryam Tidjani
Yonekura, Satoru
Roh, Whijae
Spencer, Christine N.
Curbelo, Irina Fernandez
Vence, Luis
Reuben, Alexandre
Johnson, Sarah
Arora, Reetakshi
Morad, Golnaz
Lastrapes, Matthew
Baruch, Erez N.
Little, Latasha
Gumbs, Curtis
Cooper, Zachary A.
Prieto, Peter A.
Wani, Khalida
Lazar, Alexander J.
Tetzlaff, Michael T.
Hudgens, Courtney W.
Callahan, Margaret K.
Adamow, Matthew
Postow, Michael A.
Ariyan, Charlotte E.
Gaudreau, Pierre-Olivier
Nezi, Luigi
Raoult, Didier
Mihalcioiu, Catalin
Elkrief, Arielle
Pezo, Rossanna C.
Haydu, Lauren E.
Simon, Julie M.
Tawbi, Hussein A.
McQuade, Jennifer
Hwu, Patrick
Hwu, Wen-Jen
NATURE MEDICINE, 2021, 27 (08) : 1432 - +
[6] Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma
Boussiotis, Vassiliki A.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (23): : 2230 - 2232
[7] A reappraisal of CTLA-4 checkpoint blockade hypothesis in cancer immunotherapy
Du, Xuexiang
Tang, Fei
Liu, Mingyue
Zheng, Pan
Liu, Yang
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 : 59 - 59
[8] CTLA-4 blockade-based immunotherapy for prostate cancer.
Fong, L
Rini, B
Kavanaugh, B
Small, E
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 185S - 185S
[9] Immunotherapy via CTLA-4 blockade with humab MDX-010
Lowy, I
ANNALS OF ONCOLOGY, 2005, 16 : 25 - 25
[10] THE EFFICACY OF CANCER IMMUNOTHERAPY RELIES ON GUT MICROBIOTA
不详
CANCER DISCOVERY, 2016, 6 (01) : 11 - 11

← 1 2 3 4 5 →